Stock ELAB ELEVAI LABS INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Elevai Labs Inc.

Equities

ELAB

US28622K1043

Market Closed - Nasdaq
Other stock markets
 02:00:00 25/05/2024 am IST 		5-day change 1st Jan Change
0.6681 USD +1.24% Intraday chart for Elevai Labs Inc. -2.48% -63.46%
19/05 Certain Common Stock of Elevai Labs, Inc. are subject to a Lock-Up Agreement Ending on 19-MAY-2024. CI
02/05 Elevai Biosciences Inc. Highlights Preclinical Data Showing Potential of In-Licensed Asset ?EL-22? for The Treatment of Obesity CI

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Elevai Labs Inc Subsidiary, Elevai Biosciences, to Present at the UCLA LA-BEST 2024 Conference
GL
Elevai Labs Inc. Reports First Quarter 2024 Financial Results
GL
Elevai Biosciences Highlights Preclinical Data Showing Potential of In-Licensed Asset “EL-22” for The Treatment of Obesity
GL
Elevai Biosciences Highlights Preclinical Data Showing Potential of In-Licensed Asset “EL-22” for The Treatment of Obesity
AQ
Elevai Labs Expands with Launch of Elevai Biosciences and Elevai Skincare Subsidiaries, Advancing the Future of Aesthetic Medicines and Exosome Skincare
GL
Elevai Labs Acquires Exclusive License to Two Myostatin Muscle Loss Prevention Assets with Plan to Develop in Combination with GLP-1 Obesity Treatments
GL
Elevai Labs Acquires Exclusive License to Two Myostatin Muscle Loss Prevention Assets with Plan to Develop in Combination with GLP-1 Obesity Treatments
AQ
Elevai Labs Highlights Global Distribution Partnership Overview: Contracts May Secure $4.9M Top Line Revenue Commitments
GL
ELEVAI Labs Enters the Taiwan Market with Signing of 5th International Distribution Agreement in 14 Months
GL
Elevai Labs Inc. Reports Record Full Year 2023 and Fourth Quarter Financial Results
GL
ELEVAI Labs Inc. Announces Issuance of Patent from U.S. Patent & Trademark Office
GL
ELEVAI LABS, Inc. Reports Strong Preliminary Unaudited Financial Performance for Fiscal Year 2023, Highlighting Significant Revenue Growth and Expanding Global Reach
GL
ELEVAI Labs, Inc. Acquires Worldwide License Agreement for Proprietary Stem Cell Manufacturing Technology
GL
ELEVAI LABS, Inc. to Participate in Upcoming Aesthetic Industry Conferences
GL
ELEVAI LABS, Inc. to Participate in Upcoming Aesthetic Industry Conferences
AQ
Elevai Labs Inc Announces Financial Results for the Quarter Ended September 30, 2023
GL
Elevai Labs Inc Announces Financial Results for the Quarter Ended September 30, 2023
AQ
ELEVAI Labs, Inc. Expands International Distribution into Europe
GL
Elevai Labs Enters into Licensing Agreement with Yuva Biosciences to Combine Exosome and Mitochondrial Technologies to Develop New Aesthetics Products
GL
Elevai Labs Enters into Licensing Agreement with Yuva Biosciences to Combine Exosome and Mitochondrial Technologies to Develop New Aesthetics Products
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ELAB Stock
  4. News Elevai Labs Inc.
  5. Press Releases